Stephens initiated coverage of Bicycle Therapeutics (BCYC) with an Equal Weight rating and $25 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics Faces Strategic Risks from Concentrated Shareholder Influence
- Bicycle Therapeutics: Promising Q3 Results and Business Progress
- Bicycle Therapeutics reports Q3 EPS (74c), consensus (78c)
- BCYC Earnings this Week: How Will it Perform?
- Bicycle Therapeutics announces presentation of MT1-MMP data